Andrew Strong, J.D.
Partner, Hogan Lovells
Andrew Strong is an experienced trusted advisor and counsel to global life sciences, pharmaceutical, and emerging technology clients on matters involving corporate formation, public and private financing, mergers and acquisitions, cross-border licensing and joint ventures, employment and executive compensation, and intellectual property.
Andrew represents public and private life sciences, pharmaceutical, and emerging technology companies as well as public and private academic and research institutions on a variety of diverse matters. He has experience starting up and selling a successful biotech company that has now grown to 600+ employees, has served and presently serves as the general counsel for several private and publicly traded drug development biotech clients, and has served as a board member and in leadership positions for NYSE, Nasdaq, and private corporations. His experience working in the c-suite and as chief legal counsel for startups, academic centers, and publicly traded corporations provides him with a unique perspective on which he draws in advising and counseling the firm's clients.
Andrew previously served as the general counsel and compliance officer for the Texas A&M University System where he was responsible for, among other things, crisis management and internal investigations for the system's 11 public universities, seven state agencies, and health science center. Additionally, he was the founding CEO of Kalon Biotherapeutics, a startup biotech company spun out of the A&M System, which he successfully grew over several years and sold to Fujifilm and Mitsubishi. Recently, Andrew cofounded and presently serves as the chairman of K2 Biolabs, a drug development company accelerator for early stage biotech companies. Andrew was appointed to and serves as the co-chair of the Cancer Prevention and Research Institute's (CPRIT) Product Development Advisory Committee.